|
|
|
|
| Symbol(s): |
GEN.CO |
| Date: |
19-Mar-13 |
| Author: |
GlobalData |
| Contributor: |
GlobalData |
| Title: |
Genmab A/S (GEN) - Financial and Strategic SWOT Analysis Review |
| Document Size: |
41 pages |
| Price: |
$125 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $125. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| Genmab A/S (GEN) - Financial and Strategic SWOT Analysis ReviewSummary Genmab A/S (Genmab) is a biotechnology company. It developsdifferentiated human antibody therapeutics for the treatment ofcancer. The company's first marketed antibody, Ofatumumab(Arzerra), is used to treat chronic lymphocytic leukemia.Ofatumumab is marketed in 26 countries under a co-development andcollaboration agreement with GlaxoSmithKline. The product pipelineof Genmab comprises Ofatumumab, Daratumumab (HuMax-CD38),Inclacumab...
| | |
|
|
